Open Access Research Article

Peripheral Neuropathies Under New Combined Antiretroviral Therapy in HIV Infection at Fann National University Hospital: Electrophysiological Aspects and Risk Factors

Seck LB1*, Magnerou MA2, Ngom NF3, Sarr MM4, Diagne NS5, Fall M5, Basse AM5, Ndoye NF5 , Diop AM2, Toure K3, Seydi M5, Ndiaye M5, Diop AG5 and Ndiaye MM5

1Department of Medical Specialties, Gaston Berger University of Saint Louis, Senegal

2Department Internal Medecine, Gynecological obstetrics and pediatrics hospital of Douala, Cameroun

3Department Medical Specialties, Bambey University, Senegal

4Department Medical Specialties, Thies University, Senegal

5Department Medical Specialties, Cheikh Anta Diop University, Senegal

Corresponding Author

Received Date: November 11, 2019;  Published Date: November 20, 2019


Introduction: Peripheral neuropathies are frequent during HIV infection, sometimes du to antiretroviral treatment. We aimed to assess electrophysiological aspects of peripheral neuropathies occurring after initiation of new combined antiretroviral therapy, and their risk factors.

Patients and Methods: We conducted a longitudinal descriptive and analytical study in the Fann National University Hospital, recruiting patients with HIV, newly treated with new highly active antiretroviral therapy. We collected clinical, electroneuromyographical and biological data.

Results: Data of 37 patients were analyzed. Sex-ratio was of 0,68; mean age was 34,32 +/- 8,03 years, and the main age group 20-40 years. The most frequent treatment combination was tenofovir + emtricitabine + efavirenz. Clinical examination found sensory neuropathy in 3 patients. Electroneuromyography confirmed these 3 cases that were sensory axonal polyneuropathy and found one case of motor axonal mononeuropathy. We did not find any correlation between neuropathy and parameters we studied.

Keywords: Neuropathies; Combined; Antiretroviral; Therapy; HIV; Fann; Electrophysiological

Abbreviations: HIV: Human Immunodeficiency Virus; ART: Antiretroviral Therapy; Cart: Combined Antriretroviral Therapy; PN: Peripheral Neuropathy; PLHIV/AIDS: People Living with HIV and/or Acquired Immunodeficiency Syndrome; CTA: Centre De Traitement Ambulatoire; HIV1: Human Immunodeficiency Virus 1; HIV2: Human Immunodeficiency Virus 2; ENMG: Electroneuromyography; BPNS: Brief Peripheral Neuropathy Screen; MRC: Medical Research Council; WHO: World Health organization; IBM SPSS: International Business Machines Corporation Statistical Package for the Social Sciences; NRTI: Nucleosidic Reverse Transcriptase Inhibitor; PWHIV: People Living with Human Immunodeficiency Virus; Nnrtis: Non Nucleosidic Reverse Transcriptase Inhibitors; FTC: Emtricitabine; TDF: Tenofovir; EFV: Efavirenz; 3TC: Lamivudine; AZT: Zidovudine; PI: Protease Inhibitor; Lpv/R: Lopinavir/Ritonavir

Signup for Newsletter
Scroll to Top